Best MOTS-c Providers in 2026 — Ranked & Reviewed
Mice are where MOTS-c, a mitochondrial-derived peptide, has been studied as a metabolic regulator and “exercise mimetic.” Being direct here: no randomized trial in humans has ever put MOTS-c to the test as a weight-loss treatment, and no use of it holds FDA approval anywhere. Our full evidence review carries the detail. Beyond the evidence gap, no compounding pharmacy may lawfully sell it either. The current status is below.
New to MOTS-c? Read our full MOTS-c guide — evidence, dosing, safety and side effects.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Why nothing is ranked here yet
MOTS-c was recommended for Section 503A's Bulk Drug Substances List by the Pharmacy Compounding Advisory Committee (PCAC) at the FDA on July 23, 2026. A recommendation is all that vote is. The FDA and HHS have to act formally before a compounding pharmacy may lawfully sell MOTS-c. And when they do, nothing about the evidence gap for weight loss specifically will have moved; our full evidence review covers that. Our catalog audit could confirm no provider selling MOTS-c in full compliance, so none is ranked here for now.
Listing a provider that cannot legally sell this yet would be worse than listing nobody, so nothing is shown. The FDA’s decision is being tracked, and a compliant provider will be ranked here the moment one exists.
How we rank, and what counts as “legit”
Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.
Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].
How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].
Frequently Asked Questions
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.